AaronThomasGerdsMDMS
Hematology • Cleveland, OHHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Assistant Professor, Medicine, Cleveland Clinic Learner College of Medicine of Case Western Reserve
Dr. Gerds is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9500 Euclid Ave
CA-60
Cleveland, OH 44195Phone+1 216-445-9840- Is this information wrong?
Summary
- Dr. Aaron Gerds completed his undergraduate degree with honors (B.A. in biology and chemistry) at Hope College in Holland, Michigan. He then obtained his M.D. from Loyola University Chicago Stritch School of Medicine. Dr. Gerds stayed at Loyola University Hospital for his Internal Medicine residency training where he also served as chief resident. This is when he first became interested in hematology while analyzing the results of clinical trials under the mentorship of Dr. Patrick Stiff. This experience led him to pursue a master’s degree in clinical research methods and epidemiology during residency. Dr. Gerds then went to Seattle where he completed his hematology/oncology fellowship at the University of Washington, Fred Hutchinson Cancer Research Center. During his fellowship, he was awarded the ASBMT’s New Investigator Award. Under the mentorship of Drs. Joachim Deeg and Bart Scott, Dr. Gerds subspecialized in treating patients with myeloproliferative neoplasms (MPNs) such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), as well as myelodsyplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), with a special emphasis on allogeneic hematopoietic cell transplantation. Dr. Gerds is also an active member of the American Society of Hematology, participating in both the Advocacy Leadership Institute and Clinical Research Training Institute, as well as serving on the Test Materials Development Committee. As Assistant Professor in Medicine (Hematology and Medical Oncology) at the Cleveland Clinic Taussig Cancer Institute, Dr. Gerds serves as the principle investigator for a number of clinical trials for the treatment of MPNs, and is focused on developing novel therapies for these patients.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2010 - 2013
Loyola University ChicagoMSc, Clinical Research Methods and Epidemiology, 2008 - 2011
Loyola University Medical CenterResidency, Internal Medicine, 2006 - 2010
Loyola University Chicago Stritch School of MedicineClass of 2006- Hope CollegeB.A., Biology and Chemistry, Cum Laude, 1998 - 2002
Certifications & Licensure
OH State Medical License 2013 - 2025
WA State Medical License 2010 - 2014
IL State Medical License 2006 - 2011- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- New Investigator Award American Society for Blood and Marrow Transplantation, 2013
- Scholar, Clinical Research Training Course American Society for Blood and Marrow Transplantation, 2012
- Alpha Omega Alpha Loyola University Stritch School of Medicine, 2010
- Join now to see all
Clinical Trials
- Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
- Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
- The National Myelodysplastic Syndromes (MDS) Study Start of enrollment: 2016 Jun 13
- Join now to see all
Publications & Presentations
PubMed
- Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice S Wang, Aaron T Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati G...> ;Blood Advances. 2024 Mar 26
- A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.Leland L Metheny, Ronald Sobecks, Christina Cho, Pingfu Fu, Seunghee Margevicius, Jiasheng Wang, Lisa Ciarrone, Shelby Kopp, Robin D Convents, Navneet Majhail, Paolo F...> ;Blood Advances. 2024 Mar 26
- Interferons in the treatment of myeloproliferative neoplasms.Pankit Vachhani, John Mascarenhas, Prithviraj Bose, Gabriela Hobbs, Abdulraheem Yacoub, Jeanne M Palmer, Aaron T Gerds, Lucia Masarova, Andrew T Kuykendall, Raajit K R...> ;Therapeutic Advances in Hematology. 2024 Jan 1
- Join now to see all
Journal Articles
- Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell TransplantationDeepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature
- Lactone synthesis via biotransformations of Gamma-hydroxyamidesTaylor, S.K., Arnold, C.R., Gerds A.T., Ide, N.D., Law K.M., Kling, D.L., Pridgeon M.G., Simons, L.J., Vyvyan, J.R., Yamaoka, J.S., Liao, M.K., Goyne, T.E., Tetrahedron: Asymmetry, 1/1/2004
Abstracts/Posters
- Interactions between Donor Activating Killer Immunoglobulin-like Receptors (KIRs) and Somatic Mutations and Their Association with Outcomes after Allogeneic Hematopoie...Aaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based TherapiesAaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic LeukemiaAaron T. Gerds, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Disease and Clinical Characteristics of Patients with Myelofibrosis Enrolled in the MOST Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Defining Treatment Strategies for MDS/MPN Overlap Syndromes61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Social Media for the Hematologist: Today and in the Future60th American Society of Hematology Annual Meeting - 12/2/2018
- Join now to see all
Other
- Cleveland Clinic shares how Twitter is helping save time and connect with patients. Read my perspective article in ASH Clinical NewsAaron Gerds
https://consultqd.clevelandclinic.org/twitter-isnt-just-for-millennials/ - New NCCN guidelines for MPNs include use on ruxolitinib but not molecular testingConsult QD
https://consultqd.clevelandclinic.org/2017/02/diagnostic-treatment-guidelines-established-myeloproliferative-neoplasms - Hematopoietic Cell Transplantation for MyelofibrosisGerds, AT, Scott, BL, Deeg, HJ, Myeloproliferative Neoplasms: Clinician's Guide for Apple iOS (Version 8.1), Mesa, Kiladjian, Harris
http://g2npublishing.com/mpn/
1/1/2014
Press Mentions
AML Research from ASH 2022: Novel Combinations and Evidence That “Less Is More”February 8th, 2023- Momelotinib Maintains Superiority over Danazol for Myelofibrosis with AnemiaDecember 14th, 2022
- Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK InhibitorDecember 1st, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Hospital Affiliations
Cleveland ClinicCleveland, Ohio
External Links
- Profilehttps://my.clevelandclinic.org/staff/17946-aaron-gerds
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
